Technology

AntiLand-Establishing Better Happiness Socially

 
 
Dr. Adi Zief-Balteriski, PHD Behavioral Science Expert and advisory to AntiLand, a truly anonymous and secure group chats messenger app that helps you mask your secret identity, make friends online and meet new people joins eHealth Radio and the Mental Health Channel.
Listen to interview with host Eric Michaels & guest Dr. Adi Zief-Balteriski discuss the following:
As an expert in behavioral health, what are some of the challenges people face using social media?
How is AntiLand an alternative to other known platforms? How is it better?
What are the benefits of being anonymous in the AntiLand community?
What type of topics are trending and how can one be part of the dialogue?
What three tips do you have for those wanting to establish a better well-being or a social tune-up in 2021?
Dr. Adi Zief-Balteriski, Ph.D., Behavioral Science Expert and Product Leader, Dr. Adi Zief-Balteriski is a psychologist and product expert. She applies her expertise as a behavioral science specialist in the field of community, wellness, technology and consumer behavior. She is also a researcher in the field of well-being, human computing interaction and technology and presents her work at universities and organizations in the Bay Area.
Previously, Adi opened a successful private practice and a consulting business and engaged in product consulting for consumer and well-being products. After working several years as a consultant for startup founders in the Bay Area, she shifted her focus towards the tech world. Adi began working on products at startups focused on the well-being of individuals and communities. Later, she worked as a product manager being part of the entire product lifecycle from ideation to launch.
Adi holds a Ph.D. in clinical psychology from Palo Alto University, L.L.B in Law and B.A in Business and IT from the Interdisciplinary Center. She is also the mother of two young children and passionate about making a positive impact on people’s well-being and advocating for the empowerment of women to succeed in modern society. She is an advisor to AntiLand.
 
Website: www.antiland.com

BioSig Technologies increases efforts in Electrophysiology and Atrial Fibrillation

 
 
Ken Londoner, the Chief Executive Officer, Founder and Director of BioSig Technologies that is working to develop and deliver the advanced signal processing solutions that will unlock the future of bio-electronic medicine, starting with the PURE EP™ System joins eHealth Radio and the Heart Health and Technology Channels.
Listen to interview with host Eric Michaels and guest Ken Londoner discuss the following:
Tell us a little bit about BioSig, the company’s mission and its efforts with in the medtech industry.
What does PURE EP help treat?
What types of current technologies are being used to treat AFib and how does your technology differ?
How is BioSig’s PURE EP reshaping the future of electrophysiology? How will this technology be used in hospitals, electrophysiology labs, and other institutions?
Tell us a little about BioSig’s subsidiary, ViralClear, and its potential antiviral candidate to treat COVID-19 patients.
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
 
 
Website: www.biosig.com
Social Media Links: Facebook: facebook.com/biosigtechnologies Linkedin: linkedin.com/company/biosig-technologies-inc- Twitter: twitter.com/BioSig_Tech

The importance of accurate and precise blood volume measurement in heart failure and critical care patients

 
Michael Feldschuh, the CEO of Daxor, an innovative medical instrumentation and biotechnology company focused on blood volume measurement joins eHealth Radio and the Health News and Technology Channels.
Listen to interview with host Eric Michaels and guest Michael Feldschuh discuss the following:
Can you tell me a bit about yourself and how you got interested in the medical technology field that led to your involvement with Daxor?
Let’s talk about BVA-100 and its benefits to physicians? How does BVA-100 differentiate from other similar technologies?
How does BVA-100 allow clinicians to provide better outcomes for their patients?
Are there any recent studies that validate BVA?
Please give us an overview of BVA-100 and how it improves outcomes for heart failure patients?
Daxor Corporation (NYSE: DXR) is an innovative medical instrumentation and biotechnology company focused on blood volume measurement. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology has the potential to improve hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved patient outcomes. Our mission is to partner with clinicians to incorporate BVA technology into standard clinical practice and improve the quality of life for patients.
 
 
Website: www.daxor.com
Social Media Links: Facebook: facebook.com/Daxorcorp  Linkedin: linkedin.com/company/daxorcorporation  Twitter: twitter.com/DaxorBVA

What is DehydraTECH and how is it revolutionizing drug delivery for many industries

 
 
Chris Bunka, the CEO of Lexaria Bioscience, a Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH™, that improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing joins eHealth Radio and the Health News and Pharmaceutical Channels.
Listen to interview with host Eric Michaels and guest Chris Bunka discuss the following:
Please tell us a little bit about yourself, how Lexaria Bioscience started and the development of the company’s technology?
What exactly are DehydraTECH and its benefits?
Can you talk about your recent announcement with British American Tobacco?
What are fat-soluble active molecules and how can your technology lower overall dosing with pharmaceutical ingredients?
What type of drugs and areas can DehydraTECH increase bio-absorption?
Lexaria Bioscience Corp.’s (OTCQX: LXRP, CSE: LXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules.
DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 - 2 hours to 10 - 20 minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules.
Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.
 
 
Website: lexariabioscience.com
Social Media Links: Facebook: facebook.com/lexariabioscience Linkedin: linkedin.com/company/lexaria-bioscience Twitter: twitter.com/LexariaBioCorp

The Future of Medical Recalls

 
 
Joan Melendez, the Founder and President at health-tech startup Xcelrate UDI joins eHealth Radio and the Health News and Technology Channels. Their technology, a medical device barcode scanning solution, identifies and prevents the use of recalled and faulty medical products and devices to improve patient safety at the point of care.
Listen to interview with host Eric Michaels and guest Joan Melendez discuss the following:
What is a Unique Device Identifier, and why has it become so relevant in recent times?
What kind of impact are medical recalls currently having on the healthcare industry and patients?
How could full-scale adoption of your barcode scanning technology change healthcare - for patients and the industry as a whole?
How can technology be better used across healthcare -- for communication, organisation, data storage?
The Closed Loop Automation Solution you’ve partnered on has introduced an electronic patient implant card. How will this benefit patients?
Tip: If you’ve had a medical device implanted or are about to, ask your doctor about how they are ensuring your implants are safe for use and how you will be notified of quality issues should your implants be recalled after they are implanted.
Founder and President Joan Melendez leads the team at Xcelrate UDI. Having been in the healthcare industry since her teens, Joan has become a passionate advocate for the safety of patients and for innovation in healthcare.
Xcelrate UDI is a healthcare technology and consulting services company that leverages the power of UDI (unique device identifier) barcode scanning technology to bridge the information gaps between data sources (provided by manufacturers and the FDA) for medical devices and physical supplies. Their vision? To be the industry’s most trusted partner in advancing UDI adoption to improve compliance with medical devices and reduce patient risk at the point of care.
 
 
Website: www.xcelrateudi.com
Social Media Links: Facebook: facebook.com/xcelrateudi  Linkedin: linkedin.com/company/xcelrate-udi  Instagram: instagram.com/xcelrateudi

Genprex, reprogramming the course of cancer and diabetes

 
 
Rodney Varner, the CEO of Genprex, a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes joins eHealth Radio and the Cancer Information Diabetes and Health News Channels.
Listen to interview with host Eric Michaels and guest Rodney Varner discuss the following:
What inspires you at Genprex?
Please give us an overview of Genprex’s gene therapies in development. What is it intended to treat, and how does it work?
Could you talk more specifically about Genprex’s lead product candidate GPX-001?
Could you please give us some insight about GPX-002, gene therapy for people with diabetes and what is it comprised of?
What are the benefits of Genprex’s targeted therapies for people with non-small cell lung cancer?
Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
 
 
Website: genprex.com
Social Media Links: Facebook: facebook.com/genprexinc  Linkedin: linkedin.com/company/genprex  Twitter: twitter.com/genprex

AI-Powered Medical Financial Aid Solution Helps Patients Access Care and Health Systems

 
Ethan Davidoff, CEO and founder of Atlas Health, the leader in philanthropic reimbursement that empowers health systems with an end-to-end solution for enrolling patients in medical financial aid programs joins eHealth Radio and the Health News and the Health Care Channels.
Listen to interview with host Eric Michaels and guest Ethan Davidoff discuss the following:
Please tell our audiences about Atlas Heath, its goals and who it serves.
Tell us about the Navigator 4.0, and the services and benefits it will provide to health systems and its users.
What are your relationships with healthcare payers and philanthropic relief programs designated to help aid hospital systems during the COVID-19 pandemic?
What benefits can Navigator 4.0 offer to 340B hospital systems who are experiencing the significant rate cuts during these unprecedented times?
Are there any financial risks to employers or hospital systems may be facing right now that Navigator 4.0 is working to solve?
Hospital systems are desperate for any type of aid during the COVID-19 pandemic. What other ways can your services provide relief for hospitals struggling with financial pressures?
How can patients who have lost their jobs and health insurance due to the COVID-19 economic crisis benefit from Atlas' Navigator 4.0 in terms of longevity?
Does Atlas’ Navigator 4.0 plan on providing relief for urgent care or walk-in clinics that receive patients for COVID-19 testing or intervention?
COVID-19 patients often also experience other related illnesses. What other ways can your services provide treatment and ensure patients will be financially and medically protected?
How have you been trying to educate under-served populations on your services? Please describe how Atlas’ Navigator 4.0 will help with the challenges for under-served populations with access to primary care services?
 
 
Atlas Health, the leader in philanthropic reimbursement, is improving and saving lives by empowering providers with an end-to-end solution for matching and enrolling patients in medical financial aid programs through its proprietary technology and AI-powered service partnership platform, Atlas Navigator. Patients receive the care they need and providers secure reimbursement for care delivered.
Ethan Davidoff is the Founder & CEO of Atlas Health with over 10 years of healthcare, enterprise software, and cyber security experience. Ethan Davidoff founded Atlas Health in 2017 and maintains the role of CEO. Under his direction, the company has become the leader in philanthropic reimbursement.
Prior to Atlas Health, Davidoff was a founding member of RiskIQ. Serving as Vice President and General Manager of Internet Security, he managed a cross-functional team to grow an emerging business unit with fortune 500 and top technology companies.
Davidoff studied business, entrepreneurship, and software development at the University of California at Berkeley and the London School of Economics.
 
 
Website: https://atlas.health
Linkedin: linkedin.com/company/atlashealth

Biotricity on a Mission to Protect Your Heart

 
 
Dr. Waqaas Al-Siddiq, PhD the Founder and CEO of Biotricity a developer of advanced remote cardiac monitoring technology joins eHealth Radio and the Heart Health and Health News Channels.
Listen to interview with host Eric Michaels and guest Dr. Waqaas Al-Siddiq discuss the following:
What is Biotricity’s mission?
What is the problem you are solving?
How does Biotricity benefit doctor and their patients?
How do the Biotricity Bioflux and Biocentrix products work?
With the increase in stress and anxiety related to Covid-19, how can Biotricity reduce the problem?
 
 
Trying to maintain a healthy heart has become more difficult in the wake of COVID-19. While the pandemic has increased remote tele-health, there are glaring vulnerabilities due to a lack of real-time cardiac monitoring. Heart attacks are on the rise as a result of patients ignoring symptoms, staying home and not going to the hospital. COVID related stress has caused a surge in cardiac health issues. Additionally, some recovering COVID patients have since developed heart issues related to the virus. As a result, the need for real-time cardiac monitoring is more important than ever.
Dr. Waqaas Al-Siddiq has been at the forefront of remote monitoring solutions. He is the founder and CEO of Biotricity, developer of advanced remote cardiac monitoring technology. Waqaas believes COVID-19 has accelerated the ongoing shift in the health landscape from a reactive system to a prevention, personalized and more efficient tech-based system.
Waqaas, is a serial entrepreneur, a former investment advisor and an expert in wireless communication technology. Academically, he was distinguished for his various innovative designs in digital, analog, embedded, and micro-electro-mechanical products. His work was published in various conferences such as IEEE and the National Communication Council.
Waqaas has held several high-level design positions in IBM, AMD, and Intel. His achievements have been numerous in both the technical and academic world. Coupled with this, Waqaas has vast experience in leading various groups through his board experience and executive roles within start-ups, mid-sized companies, and non-profits.
Waqaas has a dual Bachelor’s degree in Computer Engineering and Economics, a Master’s in Computer Engineering from Rochester Institute of Technology, and a Master’s in Business Administration from Henley Business School. He also holds a Doctorate in Business with a specialty in Transformative Innovations and Billion Dollar Markets.
 
 
Website: https://www.biotricity.com
Social Media Links: Facebook: facebook.com/biotricity Linkedin: linkedin.com/company/biotricity-measuring-vitals  Twitter: twitter.com/biotricity_inc

A Smarter Way to Consume Cannabis

 
 
Izzy Kirsh, founder and CEO of Mode, a company focused on managing cannabis dosing responsibly joins eHealth Radio and the Cannabis & Pain Management Channels.
Listen to interview with host Eric Michaels and guest Izzy Kirsh discuss the following:
Mode has a disruptive approach to managing cannabis intake, what is your mission?
What is the problem you are solving?
How did you discover the need to manage cannabis intake?
How does Mode work?
How can Mode help those with chronic pain, anxiety or other health related issues?
Where can Mode be purchased?
 
 
Izzy Kirsh is Founder and Co-chief Executive Officer of Mode. A serial entrepreneur, designer and inventor, Izzy has more than a decade of experience leading hardware and software engineering, branding and marketing teams across a variety of products and digital properties. Izzy’s past entrepreneurial endeavors include IoT hardware startup, Altitude Co., and travel app, AirportChatter. His inspiration for Mode came after a personal injury highlighted the lack of proper cannabinoid dosing devices. With Mode’s personalized cannabis dosing, Izzy aims to create a healthier, happier and more productive society.
 
 
Website: https://mode.co
Social Media Links: Facebook: facebook.com/joinmode Instagram: instagram.com/mode.co Twitter: twitter.com/JoinMode

How Light Therapy Boosts Brain Health

 
 
Terry Moore, Founder & CEO of HomeoLux, a health and technology company that designs wellness products based on cutting-edge science joins eHealth Radio and the Health News and Technology Channels. Their mission is to enable providers to offer care at any time from any location in the world.
Listen to interview with host Eric Michaels and guest Terry Moore discuss the following:
Tell us about the impact of Alzheimer’s disease and why you established HomeoLux?
What is 40hz light therapy and how does it boost brain function?
Who benefits most from 40hz light therapy?
What does the future for cognitive health look like?
What are your personal wellness routines for maintaining cognitive health?
TIP: People try all kinds of crazy routines and habits to lead the healthiest lives possible, mentally and physically. Triathlons, taking psychedelic drugs, etc. These all lead to intense brain experiences, but they won’t bring the heightened brain activity and clarity that 40hz light therapy will give you as it cleans your brain. It can also be simply adopted into any daily routine without disrupting your current day to day activities.
 
 
Terry Moore is the CEO and Founder of HomeoLux. Known as a Business Philosopher, Terry has been a lifelong leader in science, and research. He came out of retirement to launch HomeoLux, a health and technology company that designs wellness products based on cutting-edge science. The company is Terry’s answer to his wife’s Alzheimer’s diagnosis and is dedicated to families battling cognitive decline.
Terry is also the founder of the Radius Foundation, a forum for exploring and gaining insight from different worldviews. He serves as a board member at The Columbia Center for Radiology Research and has popular TED Talks that examine how to master even the most simplistic life skills.
 
Website: https://homeolux.com
Social Media Links: Facebook: facebook.com/homeolux  Instagram: instagram.com/homeolux  Linkedin: linkedin.com/company/homeolux